Addex Unveils Research on mGlu7 Targeting for Anxiety Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy ADXN?
Source: Newsfilter
- Research Publication: Addex Therapeutics published findings in Molecular Psychiatry indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators could be transformative for treating anxiety and post-traumatic stress disorder (PTSD), highlighting innovative prospects in this field.
- Mechanism of Action: In the study, ADX71743 effectively disrupted the reconsolidation of fear memories in rodent models, demonstrating the drug's ability to significantly decrease fear reinstatement within a defined time window after memory recall, offering a new therapeutic avenue that may reduce reliance on traditional medications.
- Cross-Species Validation: Electrophysiological analyses revealed similar synaptic effects of ADX71743 in both rat and human brain tissues, enhancing understanding of mGlu7 target engagement and providing early translational validation for central nervous system drug development.
- Broad Market Potential: The research findings not only offer a new direction for drug development in treating anxiety and trauma-related disorders but also have the potential to enhance Addex's competitive position in the neuropsychiatric market, further solidifying its standing in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADXN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Addex's Novel GABAB PAM Shows Robust Efficacy in Chronic Cough Model
- Clinical Trial Results: Addex Therapeutics demonstrated robust anti-tussive activity of its GABAB positive allosteric modulator in a non-human primate chronic cough model, significantly reducing citric acid-induced cough frequency, indicating its potential as a once-daily treatment option for chronic cough patients.
- Efficacy Comparison: The drug candidate's antitussive efficacy was comparable to baclofen in the chronic cough model, and it outperformed nalbuphine, baclofen, and codeine in guinea pig models, suggesting a competitive edge in addressing the urgent need for novel therapeutics in this area.
- Tolerability Advantage: The GABAB PAM candidate exhibited better tolerability and a wider therapeutic margin compared to baclofen and codeine, which may attract more patients to this treatment option, thereby enhancing Addex's market share in the biopharmaceutical sector.
- Strategic Development Focus: Addex is advancing its independent GABAB PAM program for chronic cough while collaborating with Indivior to develop the drug for substance use disorders, showcasing its broad application potential in neurological disorders and strategic positioning in the market.
See More
Addex's Novel GABAB PAM Shows Strong Efficacy in Chronic Cough Model
- Significant Drug Efficacy: Addex Therapeutics' novel GABAB positive allosteric modulator demonstrated robust anti-tussive activity in a non-human primate chronic cough model, significantly reducing citric acid-induced cough frequency with efficacy comparable to baclofen, but with fewer side effects, indicating a wider therapeutic margin and improved tolerability.
- Supporting Preclinical Research: Previous studies in guinea pigs also showed reductions in cough frequency and increased cough latency without signs of tolerance after repeated dosing, further validating the candidate's potential in chronic cough treatment.
- Importance of Therapeutic Context: Chronic cough is a challenging condition with limited approved therapies, and Addex's PAM aims to deliver the therapeutic benefits of baclofen while enhancing selectivity, tolerability, and durability by targeting an allosteric site of the GABAB receptor, which holds significant clinical implications.
- Optimistic Company Outlook: CEO Tim Dyer emphasized that the new primate data, combined with prior preclinical findings, supports the therapeutic potential of the GABAB PAM program, indicating that the company is expanding its portfolio of small-molecule allosteric modulators for neurological and psychiatric disorders.
See More
Addex Unveils Research on mGlu7 Targeting for Anxiety Treatment
- Research Publication: Addex Therapeutics published findings in Molecular Psychiatry indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators could be transformative for treating anxiety and post-traumatic stress disorder (PTSD), highlighting innovative prospects in this field.
- Mechanism of Action: In the study, ADX71743 effectively disrupted the reconsolidation of fear memories in rodent models, demonstrating the drug's ability to significantly decrease fear reinstatement within a defined time window after memory recall, offering a new therapeutic avenue that may reduce reliance on traditional medications.
- Cross-Species Validation: Electrophysiological analyses revealed similar synaptic effects of ADX71743 in both rat and human brain tissues, enhancing understanding of mGlu7 target engagement and providing early translational validation for central nervous system drug development.
- Broad Market Potential: The research findings not only offer a new direction for drug development in treating anxiety and trauma-related disorders but also have the potential to enhance Addex's competitive position in the neuropsychiatric market, further solidifying its standing in the biopharmaceutical industry.
See More
Addex's Spin-Out Neurosterix Initiates Phase 1 Study of NTX-253 for Schizophrenia
- Clinical Trial Launch: Addex Therapeutics' spin-out Neurosterix has initiated a Phase 1 clinical study of NTX-253, aimed at evaluating its safety and tolerability in healthy volunteers, marking a significant advancement in the treatment of schizophrenia.
- Funding Background: Neurosterix was spun out from Addex in April 2024, raising $65 million in Series A financing, demonstrating strong market interest in its novel small molecule allosteric modulators and enhancing its research capabilities.
- Innovative Therapy Potential: NTX-253, as a selective positive allosteric modulator of the M4 receptor, may offer a differentiated efficacy and safety profile compared to traditional dopamine antagonists, indicating a new direction in schizophrenia treatment.
- Market Outlook: By selectively modulating the M4 receptor, NTX-253 is expected to reduce psychotic symptoms while avoiding the side effects associated with traditional medications, potentially securing a significant position in the schizophrenia treatment market.
See More
Addex Amends $3.3 Million At-The-Market Offering Agreement
- Agreement Amendment: Addex Therapeutics has amended its At-The-Market Offering Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs up to an aggregate offering price of $3.3 million, enhancing financial flexibility to support R&D for neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright & Co. a 3% sales commission, which will impact the company's liquidity and potentially influence future R&D investments.
- Market Sales Method: H.C. Wainwright & Co. will sell ADSs through legally permitted market methods, ensuring that the company can flexibly adjust its sales strategy based on market conditions, thereby optimizing capital utilization.
- No Sales Obligation: Addex is not obligated to sell ADSs, providing the flexibility to make strategic decisions based on market conditions and internal needs, thus reducing financial risk.
See More
Addex Amends ATM Agreement with H.C. Wainwright for $3.3M Offering
- Financing Plan Revision: Addex Therapeutics announced an amendment to its ATM Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs with an aggregate offering price of up to $3.3 million, aimed at enhancing funding flexibility to support the development of neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright a 3% sales commission, a structure that incentivizes the agent to actively promote the sale of ADSs, potentially accelerating capital raising efforts.
- Market Sales Flexibility: Addex retains the flexibility to determine the timing and quantity of ADS sales based on market conditions and company needs, which will help the company optimize its financing strategy in an uncertain market environment.
- Risk Management Measures: The agreement includes customary indemnification and contribution rights, ensuring that Addex can effectively manage potential legal risks during the sales process, thereby protecting the company's long-term interests.
See More
Addex's Novel GABAB PAM Shows Robust Efficacy in Chronic Cough Model
- Clinical Trial Results: Addex Therapeutics demonstrated robust anti-tussive activity of its GABAB positive allosteric modulator in a non-human primate chronic cough model, significantly reducing citric acid-induced cough frequency, indicating its potential as a once-daily treatment option for chronic cough patients.
- Efficacy Comparison: The drug candidate's antitussive efficacy was comparable to baclofen in the chronic cough model, and it outperformed nalbuphine, baclofen, and codeine in guinea pig models, suggesting a competitive edge in addressing the urgent need for novel therapeutics in this area.
- Tolerability Advantage: The GABAB PAM candidate exhibited better tolerability and a wider therapeutic margin compared to baclofen and codeine, which may attract more patients to this treatment option, thereby enhancing Addex's market share in the biopharmaceutical sector.
- Strategic Development Focus: Addex is advancing its independent GABAB PAM program for chronic cough while collaborating with Indivior to develop the drug for substance use disorders, showcasing its broad application potential in neurological disorders and strategic positioning in the market.
See More
Addex's Novel GABAB PAM Shows Strong Efficacy in Chronic Cough Model
- Significant Drug Efficacy: Addex Therapeutics' novel GABAB positive allosteric modulator demonstrated robust anti-tussive activity in a non-human primate chronic cough model, significantly reducing citric acid-induced cough frequency with efficacy comparable to baclofen, but with fewer side effects, indicating a wider therapeutic margin and improved tolerability.
- Supporting Preclinical Research: Previous studies in guinea pigs also showed reductions in cough frequency and increased cough latency without signs of tolerance after repeated dosing, further validating the candidate's potential in chronic cough treatment.
- Importance of Therapeutic Context: Chronic cough is a challenging condition with limited approved therapies, and Addex's PAM aims to deliver the therapeutic benefits of baclofen while enhancing selectivity, tolerability, and durability by targeting an allosteric site of the GABAB receptor, which holds significant clinical implications.
- Optimistic Company Outlook: CEO Tim Dyer emphasized that the new primate data, combined with prior preclinical findings, supports the therapeutic potential of the GABAB PAM program, indicating that the company is expanding its portfolio of small-molecule allosteric modulators for neurological and psychiatric disorders.
See More
Addex Unveils Research on mGlu7 Targeting for Anxiety Treatment
- Research Publication: Addex Therapeutics published findings in Molecular Psychiatry indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators could be transformative for treating anxiety and post-traumatic stress disorder (PTSD), highlighting innovative prospects in this field.
- Mechanism of Action: In the study, ADX71743 effectively disrupted the reconsolidation of fear memories in rodent models, demonstrating the drug's ability to significantly decrease fear reinstatement within a defined time window after memory recall, offering a new therapeutic avenue that may reduce reliance on traditional medications.
- Cross-Species Validation: Electrophysiological analyses revealed similar synaptic effects of ADX71743 in both rat and human brain tissues, enhancing understanding of mGlu7 target engagement and providing early translational validation for central nervous system drug development.
- Broad Market Potential: The research findings not only offer a new direction for drug development in treating anxiety and trauma-related disorders but also have the potential to enhance Addex's competitive position in the neuropsychiatric market, further solidifying its standing in the biopharmaceutical industry.
See More
Addex's Spin-Out Neurosterix Initiates Phase 1 Study of NTX-253 for Schizophrenia
- Clinical Trial Launch: Addex Therapeutics' spin-out Neurosterix has initiated a Phase 1 clinical study of NTX-253, aimed at evaluating its safety and tolerability in healthy volunteers, marking a significant advancement in the treatment of schizophrenia.
- Funding Background: Neurosterix was spun out from Addex in April 2024, raising $65 million in Series A financing, demonstrating strong market interest in its novel small molecule allosteric modulators and enhancing its research capabilities.
- Innovative Therapy Potential: NTX-253, as a selective positive allosteric modulator of the M4 receptor, may offer a differentiated efficacy and safety profile compared to traditional dopamine antagonists, indicating a new direction in schizophrenia treatment.
- Market Outlook: By selectively modulating the M4 receptor, NTX-253 is expected to reduce psychotic symptoms while avoiding the side effects associated with traditional medications, potentially securing a significant position in the schizophrenia treatment market.
See More
Addex Amends $3.3 Million At-The-Market Offering Agreement
- Agreement Amendment: Addex Therapeutics has amended its At-The-Market Offering Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs up to an aggregate offering price of $3.3 million, enhancing financial flexibility to support R&D for neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright & Co. a 3% sales commission, which will impact the company's liquidity and potentially influence future R&D investments.
- Market Sales Method: H.C. Wainwright & Co. will sell ADSs through legally permitted market methods, ensuring that the company can flexibly adjust its sales strategy based on market conditions, thereby optimizing capital utilization.
- No Sales Obligation: Addex is not obligated to sell ADSs, providing the flexibility to make strategic decisions based on market conditions and internal needs, thus reducing financial risk.
See More
Addex Amends ATM Agreement with H.C. Wainwright for $3.3M Offering
- Financing Plan Revision: Addex Therapeutics announced an amendment to its ATM Agreement with H.C. Wainwright & Co., allowing for the sale of ADSs with an aggregate offering price of up to $3.3 million, aimed at enhancing funding flexibility to support the development of neurological disorders.
- Sales Commission Structure: Under the new agreement, Addex will pay H.C. Wainwright a 3% sales commission, a structure that incentivizes the agent to actively promote the sale of ADSs, potentially accelerating capital raising efforts.
- Market Sales Flexibility: Addex retains the flexibility to determine the timing and quantity of ADS sales based on market conditions and company needs, which will help the company optimize its financing strategy in an uncertain market environment.
- Risk Management Measures: The agreement includes customary indemnification and contribution rights, ensuring that Addex can effectively manage potential legal risks during the sales process, thereby protecting the company's long-term interests.
See More
